{"title":"A common TBP-binding site mutation elevates γ-globin levels by competitive globin switching change in β-thalassemia.","authors":"Mengyang Song, Xiaolei Wei, Hualei Luo, Jueheng Wang, Yuhua Ye, Lang Qin, Chao Niu, Yong Long, Xingmin Wang, Congwen Shao, Miao Yu, Feng Gu, Xinhua Zhang, Xiangmin Xu","doi":"10.1182/bloodadvances.2024013695","DOIUrl":null,"url":null,"abstract":"<p><p>β-thalassemia is a common monogenic disorder caused by genetic defects in β-globin genes (HBB), resulting in imbalanced synthesis of α-/β-globin and ineffective erythropoiesis. It has been well documented that β-thalassemia patients, or even carriers, mostly experience re-activation of fetal hemoglobin (Hb F), but its underlying mechanisms are incompletely understood. We took advantage of a previously established cohort of 1142 β-thalassemia patients with diverse thalassemic mutations subjected to targeted next-generation sequencing. Genotype-phenotype association studies demonstrated that the HBB: c. -78A>G showed a remarkable effect on the elevation of Hb F levels compared to other β-thalassemic mutations. To experimentally validate the conclusion above, the RNP transfection complex through homology-directed repair (HDR) by electroporation was performed, from which we observed a consistent increase of Hb F expression in both HUDEP-2 and primary CD34+ cell lines. Furthermore, ChIP-qPCR, Dual-luciferase reporter assay, and circular chromosome conformation capture (4C) assays validated a decreased occupancy of the HBB TATA-Box by TBP, leading to boosted expression of γ-globin genes by enhanced interaction between locus control regions (LCRs) and γ-globin gene promoters. The patient-based investigation and experimental validations presented in this study might lead to a better understanding of stage-specific globin-gene expression mediated by competitive binding of distal enhancers (LCRs).</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":""},"PeriodicalIF":7.4000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood advances","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1182/bloodadvances.2024013695","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
β-thalassemia is a common monogenic disorder caused by genetic defects in β-globin genes (HBB), resulting in imbalanced synthesis of α-/β-globin and ineffective erythropoiesis. It has been well documented that β-thalassemia patients, or even carriers, mostly experience re-activation of fetal hemoglobin (Hb F), but its underlying mechanisms are incompletely understood. We took advantage of a previously established cohort of 1142 β-thalassemia patients with diverse thalassemic mutations subjected to targeted next-generation sequencing. Genotype-phenotype association studies demonstrated that the HBB: c. -78A>G showed a remarkable effect on the elevation of Hb F levels compared to other β-thalassemic mutations. To experimentally validate the conclusion above, the RNP transfection complex through homology-directed repair (HDR) by electroporation was performed, from which we observed a consistent increase of Hb F expression in both HUDEP-2 and primary CD34+ cell lines. Furthermore, ChIP-qPCR, Dual-luciferase reporter assay, and circular chromosome conformation capture (4C) assays validated a decreased occupancy of the HBB TATA-Box by TBP, leading to boosted expression of γ-globin genes by enhanced interaction between locus control regions (LCRs) and γ-globin gene promoters. The patient-based investigation and experimental validations presented in this study might lead to a better understanding of stage-specific globin-gene expression mediated by competitive binding of distal enhancers (LCRs).
期刊介绍:
Blood Advances, a semimonthly medical journal published by the American Society of Hematology, marks the first addition to the Blood family in 70 years. This peer-reviewed, online-only, open-access journal was launched under the leadership of founding editor-in-chief Robert Negrin, MD, from Stanford University Medical Center in Stanford, CA, with its inaugural issue released on November 29, 2016.
Blood Advances serves as an international platform for original articles detailing basic laboratory, translational, and clinical investigations in hematology. The journal comprehensively covers all aspects of hematology, including disorders of leukocytes (both benign and malignant), erythrocytes, platelets, hemostatic mechanisms, vascular biology, immunology, and hematologic oncology. Each article undergoes a rigorous peer-review process, with selection based on the originality of the findings, the high quality of the work presented, and the clarity of the presentation.